Well we'll know soon enough. The new CEO isn't taking a salary, only stock. Earnings are coming out May 11, and I expect them to post less of a loss than expected, and to guide for a profit, either in the June or Sept qtr. Bottom line is, the backlog has 6,5% margins attached, and the CEO said in the Dec qtr earnings report to expect higher than that. He also said revenues will grow in 2015 as they did in 2014. Well they grew 20% in 2014. If you crunch the numbers on $800M revenues and 7% margins, the company would post around $1 in EPS from the June qtr 15 to the June qtr 16.. I guess you can look at it as the glass is half empty, but I think STRL is on the comeback trail. Time will tell.
I'm buggin, because your story doesn't add up. That is, if you were in the industry for so long, why would you give us a number that can't be verified, and then state that Darkstools and Hedgies will become quite familiar with this number. You must have known that the SEC would not discuss this number with anyone, and there would be no way for us to verify it, nor follow the case with it.
Lastly it is noteworthy that you called it a case #, as this is just a receipt number for a complaint, and if there was a case, there would be another number given. I would think you'd have know this also.
Yes, but my question was and still is, why did you give a TCR #, when it can not be verified ? Also why did you call it a case # ? The SEC said it is only a reference # to a complaint, not a case #. Here is what you said in your post...
" Darkstools and Hedgies will be quite familiar with this case number below in the coming days."
ri66- There is no verification of the number you gave. The SEC simply stated that there is a 13 digit number is given to the complaintant, and would not verify any given number or discuss it at all. That's it, end of story.
Just talked with SEC, and it is true that a complaint is given a 13 digit number for reference. However they told me that number is confidential, and is not discussed publically. Therefore my question would be- why did you list the case number, when there is no way for us to follow the case ?
nephrologycat- Do the GI side effects concern you ? It does appear around 20% of the patients in the trials dropped out for that reason. thanks
ri66- could you please tell me where to go to look at other filed cases to see the 13 digit number on them as yours has.
ri66- I went to the SEC website, and after doing some digging, saw a case number given for a specific complaint/whistleblower from a filed TCR form. However the case number I viewed had two capital letters, and six numbers. Your case number has 13 numbers and no letters. Could you pleae tell me where to go to see past TCR case numbers with the same 13 number digits as yours.
First of all, Japan. The drug has been selling there for a year now. From my understanding, the drug has been approved there for the use in chronic kidney disease on dialysis as well as early stage renal disease with anemia. So in essence, the supposed triple revenues for the use of Auyxia in early stage renal disease is being realized by Torri in Japan. So how well has Torri been doing ?
Looks like the equivelent of $38M max for 2015 is being guided for. The big question now. How many fold revenues will the US produce for Auryxia vs Japan. That is, assuming the FDA approves it for the use of early stage renal disease ? Lastly, what profit margins can we expect KERX to show for Auyxia ?
Does. Torri sell Auryxia for use in both chronic kidney disease patients on dialysis, and early stage renal disease patients with anemia ? I think the use for both was Japanese FDA approved- no ? If so, how much more/year in revenues in the US can we expect over Japan ? 2x, 3x, 4x, 5x, or more ?
I just looked at institutional holding, and it was 46.5M as of last count. Then there is around 2.5M held by insiders, and there is total 58.5M fully diluted shares. That would mean there are 9.5M shares in the float- yet there were 11M shares short as of 4/15. Assuming institutions aren't lending out there shares, how is that possible ?
What do you think of this analysis by Stifel ?
KERX (11.35) target was lowered by Stifel yesterday -
Keryx Biopharma target lowered to $17 at Stifel; Buy (11.45 ) : Stifel lowers their KERX tgt to $17 from $19 as they believe timing around the completion of additional Part D formulary reviews likely implies the full-impact of any progress on the reimbursement front will not materialize until 3Q15 -- at which point sentiment around pending YE15 P3 CKD data should mitigate some of the characteristic volatility associated with weekly prescription data. Firm lowers PT on these tempered launch projections -- with their ests now conservatively assuming